Gregory Eschenauer, Pharm.D., appointed to National Institutes of Health COVID-19 Treatment Guideline Panel
Gregory Eschenauer, PharmD, clinical associate professor and clinical pharmacist, Michigan Medicine, has been appointed to represent the Society of Infectious Diseases Pharmacists (SIDP) on the National Institutes of Health COVID-19 Treatment Guideline Panel. His appointment is effective immediately. He replaces Susan Davis, PharmD’02, who stepped down in consideration of her new administrative role at Wayne State University.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, convened the Panel in late March 2020. The Panel is composed of academicians, clinicians, and representatives from multiple professional societies and government agencies.
The goal of the Guideline Panel is to provide current, evidence-based recommendations for the care of patients with COVID-19. Dr. Eschenauer’s role will be to review new literature pertaining to COVID-19 therapeutics, assist in the writing and development of updates, and take part in Panel discussions regarding such changes.
Dr. Eschenauer is a clinical associate professor in the Department of Clinical Pharmacy at the University of Michigan College of Pharmacy and clinical pharmacy specialist in infectious diseases at Michigan Medicine. Dr. Eschenauer received his Doctor of Pharmacy from Butler University and completed his pharmacy practice and infectious diseases specialty residencies at the University of Michigan.
Dr. Eschenauer is an expert in infectious disease and antimicrobial stewardship. He is a member of the Michigan Medicine Antimicrobial Stewardship Program, a multi-disciplinary team that works to ensure effective and appropriate utilization of antimicrobials for hospitalized patients, reevaluate treatments of common infections, and set best practices. Accordingly, the Antimicrobial Stewardship Program has been responsible for developing and maintaining institutional COVID-19 therapeutic guidelines within Michigan Medicine. During the height of the COVID-19 pandemic, the Program also performed observational research to inform their local practice while awaiting the results of clinical trials.
The Panel’s recommendations inform clinicians around the world about the best care for patients with COVID-19. Dr. Eschenauer’s expertise and contributions to the Panel will affect patient care worldwide. He joins Michigan Pharmacy alumna Alice Pau, PharmD’83, on the Panel.